NPS Pharmaceuticals entered into an agreement to a merger of equals with Enzon Pharmaceuticals. The merger deal could be worth up to US$1.6 B. The combined company would continue to market ABELCET®, ONCASPAR®, DEPOCYT® and ADAGEN® in addition to unmet therapeutic areas such as osteoporosis and gastrointestinal disorders.